Most people think about fat as the part they can see: belly, thighs, arms, face. That is understandable. Clothes fit differently and the mirror gives feedback every day.

But medically, the fat you cannot see often matters more. Visceral fat sits around the organs. Liver fat accumulates inside the liver itself. These fat stores are closely linked with insulin resistance, high triglycerides, fatty liver disease, inflammation, and cardiovascular risk.

The Élan target is not simply lower weight. The better target is healthier body composition: less visceral and liver fat, preserved muscle, and a realistic plan for maintenance.

Visible fat and visceral fat are not the same problem

Subcutaneous fat is the fat under the skin. It affects body shape, comfort, and appearance. Visceral fat is deeper, packed around abdominal organs. It behaves more like an active endocrine organ than passive storage.

In the Framingham Heart Study, Fox CS et al. (Circulation, 2007; n=3,001) found that visceral fat was more closely associated with metabolic risk factors than subcutaneous fat. This is why two people with the same weight can have very different health risk.

Why liver fat matters

The liver is central to glucose and lipid metabolism. When excess fat builds up inside the liver, the liver becomes less responsive to insulin and produces more glucose and triglyceride-rich particles. Over time, this can contribute to type 2 diabetes, high triglycerides, hypertension, and metabolic dysfunction-associated steatotic liver disease.

For patients, this means the question is not only, How much weight did I lose? It is also, What kind of weight did I lose, and did my metabolic risk improve?

Where GLP-1 medicines fit

Semaglutide and tirzepatide reduce appetite and body weight, but their value may extend beyond visible weight loss. In a phase 2 trial in non-alcoholic steatohepatitis, Newsome PN et al. (NEJM, 2021; n=320) found higher rates of NASH resolution with semaglutide than placebo, although fibrosis improvement was not significantly better. In SYNERGY-NASH, Loomba R et al. (NEJM, 2024; n=190) found tirzepatide improved MASH resolution versus placebo in patients with MASH and fibrosis.

These studies do not mean GLP-1 medication is a casual liver treatment. They do support a broader view: for the right patient, weight management is also metabolic risk management.

Muscle preservation still matters

Losing visceral and liver fat is good. Losing muscle is not. Rapid weight loss without enough protein and resistance training can reduce lean tissue, strength, and resting energy expenditure. This is why Élan does not frame treatment as a race to a lower number.

What Élan should monitor

A better medical programme tracks more than kilograms. Depending on the patient, monitoring may include waist circumference, blood pressure, HbA1c or fasting glucose, lipid profile, liver enzymes, body composition, strength, protein intake, and medication tolerance.

This is the practical difference between cosmetic weight loss and medical weight management. The first asks, Are you smaller? The second asks, Are you metabolically healthier, stronger, and more likely to maintain the result?

Sources

Fox CS et al., Circulation, 2007;116:39-48; Framingham Heart Study, n=3,001.
Newsome PN et al., New England Journal of Medicine, 2021;384:1113-1124; phase 2 NASH trial, n=320.
Loomba R et al., New England Journal of Medicine, 2024;391:299-310; SYNERGY-NASH tirzepatide trial, n=190.

If you are using Ozempic, Wegovy, or Mounjaro and want to know whether your weight loss is improving metabolic health, book a medical consultation with Élan Clinic.